PPP2R1A Mutation: A Critical Amplifier for Immune Checkpoint Blockade Therapy Efficacy

Yuanzhuo Gu; Zhengkui Zhang; Fangfang Zhou

doi:10.1002/mco2.70511

MedComm ›› 2025, Vol. 6 ›› Issue (12) :e70511 DOI: 10.1002/mco2.70511

HIGHLIGHT

PPP2R1A Mutation: A Critical Amplifier for Immune Checkpoint Blockade Therapy Efficacy

Author information +

History +

PDF

Cite this article

Download citation ▾

Yuanzhuo Gu, Zhengkui Zhang, Fangfang Zhou. PPP2R1A Mutation: A Critical Amplifier for Immune Checkpoint Blockade Therapy Efficacy. MedComm, 2025, 6(12): e70511 DOI:10.1002/mco2.70511

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Y. Dai, A. Knisely, M. Yano, et al., “PPP2R1A Mutations Portend Improved Survival After Cancer Immunotherapy,” Nature 644 (2025): 537–546.

[2]	Z. Peng, H. Li, Y. Gao, et al., “Sintilimab Combined With Bevacizumab in Relapsed or Persistent Ovarian Clear Cell Carcinoma (INOVA): A Multicentre, Single-Arm, Phase 2 Trial,” Lancet Oncology 25 (2024): 1288–1297.

[3]	X. Ma, N. Riaz, R. M. Samstein, et al., “Functional Landscapes of POLE and POLD1 Mutations in Checkpoint Blockade-Dependent Antitumor Immunity,” Nature Genetics 54 (2022): 996–1012.

[4]	B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577 (2020): 549–555.

[5]	W. S. Ho, H. Wang, D. Maggio, et al., “Pharmacologic Inhibition of Protein Phosphatase-2A Achieves Durable Immune-Mediated Antitumor Activity When Combined With PD-1 Blockade,” Nature Communications 9 (2018): 2126.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.